Literature DB >> 18786985

Development of dual-class antiretroviral drug resistance in a child coinfected with HIV and tuberculosis: a case report from KwaZulu-Natal, South Africa.

Richard A Murphy1, Holly France, Henry Sunpath, Michelle L Gordon, Vincent C Marconi, Daniel R Kuritzkes, Kenneth McIntosh.   

Abstract

The treatment of concurrent HIV and tuberculosis (TB) in children <3 years of age has not been well-studied and is complicated by potential drug-drug interactions. The recommended antiretroviral therapy (ART) in coinfected children in South Africa consists of full-strength ritonavir, lamivudine and stavudine. We report on a child initiated on this regimen, during concurrent TB treatment, who promptly developed an adverse reaction, virologic failure and dual-class antiretroviral drug resistance, compromising subsequent salvage ART.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18786985      PMCID： PMC2734312          DOI： 10.1093/tropej/fmn074

Source DB:  PubMed          Journal:  J Trop Pediatr        ISSN： 0142-6338            Impact factor:   1.165


  6 in total

1.  Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin.

Authors:  S Moreno; D Podzamczer; R Blázquez; J A Iribarren; E Ferrer; J Reparaz; J M Peña; E Cabrero; L Usán
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

2.  Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.

Authors:  S A Nachman; K Stanley; R Yogev; S Pelton; A Wiznia; S Lee; L Mofenson; S Fiscus; M Rathore; E Jimenez; W Borkowsky; J Pitt; M E Smith; B Wells; K McIntosh
Journal:  JAMA       Date:  2000-01-26       Impact factor: 56.272

3.  High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.

Authors:  Florence Doualla-Bell; Ava Avalos; Bluma Brenner; Tendani Gaolathe; Madisa Mine; Simani Gaseitsiwe; Maureen Oliveira; Daniella Moisi; Ndwapi Ndwapi; Howard Moffat; Max Essex; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

4.  Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age.

Authors:  Ellen Gould Chadwick; John H Rodman; Paula Britto; Christine Powell; Paul Palumbo; Katherine Luzuriaga; Michael Hughes; Elaine J Abrams; Patricia M Flynn; William Borkowsky; Ram Yogev
Journal:  Pediatr Infect Dis J       Date:  2005-09       Impact factor: 2.129

5.  Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.

Authors:  José Luis Jiménez; Salvador Resino; Alberto Martinez-Colom; Jose Ma Bellón; Ma Angeles Muñoz-Fernández
Journal:  J Antimicrob Chemother       Date:  2005-09-29       Impact factor: 5.790

6.  Epidemiology of HIV in South Africa--results of a national, community-based survey.

Authors:  Catherine Connolly; Olive Shisana; Olive Shishana; Mark Colvin; David Stoker
Journal:  S Afr Med J       Date:  2004-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.